Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 6/20 | 0.52 |
| ▸ | NLRP3 | Q96P20 | 8/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29974698 | 1.00 | IL1B (0.52) | IL1BNLRP3TRPV1HDAC4HDAC6 | |
| SCHEMBL29326149 | 1.00 | IL1B (0.52) | IL1BNLRP3TRPV1HDAC4HDAC6 | |
| SCHEMBL29326121 | 0.95 | IL1B (0.47) | IL1BNLRP3TRPV1HDAC4HDAC6 | |
| SCHEMBL27182184 | 0.91 | IL1B (0.49) | IL1BNLRP3TRPV1HDAC4HDAC6 | |
| SCHEMBL29155911 | 0.90 | TRPV1 (0.43) | IL1BNLRP3TRPV1HDAC4HDAC6 | |
| SCHEMBL30684797 | 0.90 | TRPV1 (0.43) | IL1BNLRP3TRPV1HDAC4HDAC6 | |
| SCHEMBL27182188 | 0.89 | IL1B (0.56) | IL1BNLRP3KCNH2 | |
| SCHEMBL31057291 | 0.87 | IL1B (0.70) | IL1BNLRP3TRPV1HDAC4HDAC6 | |
| SCHEMBL29326142 | 0.86 | IL1B (0.44) | IL1BNLRP3HDAC4HDAC6MAPT | |
| SCHEMBL29326123 | 0.86 | NLRP3 (0.46) | IL1BNLRP3HDAC4HDAC6IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347571-B1 | TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. | HOFFMANN LA ROCHE (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-12421209-B2 | Compounds | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250276958-A1 | COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250197370-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240132471-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-04-25 | — | — | US | disclosed |
| EP-4347571-A1 | TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| EP-4345097-A1 | SUBSTITUTED TRIAZINE COMPOUND | Astellas Pharma Inc. (JP) | 2024-04-03 | — | — | EP | disclosed |
| WO-2022253936-A1 | TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. | F. HOFFMANN-LA ROCHE AG (CH) | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421209-B2 | Compounds | C5, RB1, RPS4X | IL1B 4014/4885NLRP3 3643/4885TRPV1 2441/4885 |
| US-20250276958-A1 | COMPOUNDS | C5, RB1, RPS4X | IL1B 4014/4885NLRP3 3643/4885TRPV1 2441/4885 |
| US-20250197370-A1 | NOVEL COMPOUNDS | RB1, CDK11B, RPS4X | IL1B 3429/4885NLRP3 3053/4885TRPV1 2844/4885 |
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | IL1B 11/4885NLRP3 1/4885TRPV1 68/4885 |
| US-20240132471-A1 | NOVEL COMPOUNDS | RB1, RPS4Y1, CDK11B | IL1B 3239/4885NLRP3 3180/4885TRPV1 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.